A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-24 and is reviewed periodically as new material appears.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Absinthe has never been illegal to import or manufacture in Australia although importation requires a permit under the Customs (Prohibited Imports) Regulation 1956 due to a restriction on importing any product containing oil of wormwood. In 2000, an amendment made all wormwood species prohibited herbs for food purposes under Food Standard 1.4.4. Prohibited and Restricted Plants and Fungi. However, this amendment was found inconsistent with other parts of the pre-existing Food Code, and it was withdrawn in 2002 during the transition between the two codes, thereby continuing to allow absinthe manufacture and importation through the existing permit-based system. These events were erroneously reported by the media as it having been reclassified from a prohibited product to a restricted product.
=== Inhibin === In both females and males, inhibin inhibits FSH production. Inhibin does not inhibit the secretion of GnRH from the hypothalamus. However, the overall mechanism differs between the sexes:
The prisoners had been transferred from the city of São Paulo to the Piranhão as punishment for bad behavior. The game famously ended in widespread fights and chaos, which led to the brutal killing and decapitation of both the deputy director and a prisoner with special privileges, with the head of the latter being put on a stake. The group has the slogan "Peace, Justice and Freedom", and makes use of the Chinese taijitu (the yin and yang symbol) as their emblem, claiming that it represents a "way to balance good and evil with wisdom". In February 2001, Idemir "Sombra" Carlos Ambrósio became the most prominent leader of the organization when he coordinated, by cell phone, simultaneous rebellions in 29 São Paulo state prisons, in which 16 prisoners were killed. "Sombra", also referred to as "father", was beaten to death in the Piranhão five months later by five PCC members in an internal struggle for the general command of the group. The PCC was initially led by César "Césinha" Augusto Roris da Silva and José "Geleião" Márcio Felício, who were responsible for a short-lived alliance with the Comando Vermelho (CV). At the time, the group adopted CV's far-left beliefs and began advocating for revolution and the destruction of Brazil's capitalist system. Geleião and Cesinha, from the Bangu Penitentiary where they were held, went on to coordinate violent attacks against public buildings.
Jones were able to determine the structure of diiron nonacarbonyl, which is produced from iron pentacarbonyl by the action of sunlight. After Mond, who died in 1909, the chemistry of metal carbonyls fell for several years in oblivion. BASF started in 1924 the industrial production of iron pentacarbonyl by a process which was developed by Alwin Mittasch. The iron pentacarbonyl was used for the production of high-purity iron, so-called carbonyl iron, and iron oxide pigment. Not until 1927 did A. Job and A. Cassal succeed in the preparation of chromium hexacarbonyl and tungsten hexacarbonyl, the first synthesis of other homoleptic metal carbonyls. Walter Hieber played in the years following 1928 a decisive role in the development of metal carbonyl chemistry. He systematically investigated and discovered, among other things, the Hieber base reaction, the first known route to metal carbonyl hydrides and synthetic pathways leading to metal carbonyls such as dirhenium decacarbonyl. Hieber, who was since 1934 the Director of the Institute of Inorganic Chemistry at the Technical University of Munich published in four decades 249 papers on metal carbonyl chemistry.
Sources: en.wikipedia.org
May 20, 2009: Mexico Mexico becomes the first Latin American country to officially enter recession, having its GDP shrink 8.22% in the first quarter of 2009, after falling 1.6% in the final quarter of 2008. To this date, it is estimated that the Mexican domestic product will shrink 5.5% in 2009. Ministry of Finances Agustin Carstens declared the country in recession on May 7, 2009, based on estimates, which were confirmed when the actual, real data was released on May 20 by INEGI.
Oligoclonal bands of IgG Kappa free-light chain (kFLC) concentrations The measurement of oligoclonal bands requires specialists labs; it is easier to measure kFLC. These two biomarkers are not only elevated in MS, but also to a lesser extent in other diseases including NMOSD. They can be used instead of dissemination in time to diagnose MS where dissemination in space is demonstrated.
=== Efficiency === The high efficiency is the most important feature of the method. In a multi step (n) synthesis using equal number of BBs (k) in every step the number of components in a forming combinatorial library (N) is: N=kn This means that the number of components increases exponentially with the number steps (cycles) while the number of the required couplings increases only linearly. If a different number of building BBs are used in the cycles (k1, k2, k3....kn) the number of the formed components is: N=k1.k2.k3...kn. This feature of the procedure offers the possibility to synthesize a practically unlimited number of compounds. For example, if 1000 BBs are used in four cycles 1 trillion compounds are expected to form. The number of needed couplings is only 4000!
=== Legal status in the United States === In the United States, kratom and its active ingredients are not scheduled under DEA guidelines. Despite the current legal status of the plant and its constituents, the legality of kratom has been turbulent in recent years. In August 2016, the DEA issued a report of intent stating that mitragynine and 7-hydroxymitragynine would undergo emergency scheduling and be placed under Schedule I classification until further notice, making kratom strictly illegal and thus hindering research on its active constituents. Following this report, the DEA faced significant public and administrative opposition in the form of a White House petition signed by 140,000 citizens and a letter to the DEA administrator backed by 51 members of the House of Representatives resisting the proposed scheduling. This opposition led the DEA to withdraw its report of intent in October 2016, allowing for unencumbered research into the potential benefits and health risks associated with mitragynine and other alkaloids in the kratom plant. Kratom and its active constituents are unscheduled and legally sold in stores and online in the United States except for a small number of states. As of June 2019, the FDA continues to warn consumers not to use kratom, while advocating for more research for a better understanding of kratom's safety profile.
Tourism in Brazil is a growing sector and key to the economies of several regions of the country. The country had 6.36 million visitors in 2015, ranking in terms of the international tourist arrivals as the main destination in South America and second in Latin America after Mexico. Revenues from international tourists reached US$6 billion in 2010, showing a recovery from the 2008–2009 economic crisis. Historical records of 5.4 million visitors and US$6.8 billion in receipts were reached in 2011. In the list of world tourist destinations, in 2018, Brazil was the 48th most visited country, with 6.6 million tourists (and revenues of 5.9 billion dollars). Natural areas are its most popular tourism product, a combination of ecotourism with leisure and recreation, mainly sun and beach, and adventure travel, as well as cultural tourism. Among the most popular destinations are the Amazon Rainforest, beaches and dunes in the Northeast Region, the Pantanal in the Center-West Region, beaches at Rio de Janeiro and Santa Catarina, cultural tourism in Minas Gerais and business trips to São Paulo. In terms of the 2024 Travel and Tourism Competitiveness Index (TTCI), which is a measurement of the factors that make it attractive to develop business in the travel and tourism industry of individual countries, Brazil ranked in the 26th place at the world's level, third in the Americas, after Canada and United States. Domestic tourism is a key market segment for the tourism industry in Brazil.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.